The 9 drugs tracked here made $43.4B of Johnson & Johnson’s 2025 revenue (46%) and lose US exclusivity by 2033. Since 2023, Johnson & Johnson has closed 5 acquisitions of $1B or more, worth $21.9B in total. Products from those deals brought in $700M in 2025 (only from the closing date).
Bars are each drug's 2025 sales as a share of Johnson & Johnson’s total revenue ($94.2B). Total includes MedTech. Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Mar 2024 | Ambrx BiopharmaJ&J, March 2024 | $2.0B | Oncology | Antibody-drug conjugates, led by ARX517 for prostate cancerAbout $1.8B net of cash acquired. | Pipeline only |
| Jul 2024 | Yellow Jersey TherapeuticsJ&J, July 2024 | $1.25B | Immunology | NM26, a bispecific antibody for atopic dermatitis | Pipeline only |
| Apr 2025 | Intra-Cellular TherapiesJ&J, April 2025 | $14.6B | Neuroscience | Caplyta, approved for schizophrenia and bipolar depression2025 sales: Caplyta $700M. From 2 April 2025 only. J&J 10-K 2025 | Approved product |
| Dec 2025 | Halda TherapeuticsJ&J, December 2025 | $3.05B | Oncology | HLD-0915, an oral prostate cancer drug in clinical trials | Pipeline only |
| Jul 2026 | Firefly BioJ&J, July 2026 | $1.0B | Oncology | An early platform for degrader-antibody conjugates in solid tumors | Pipeline only |
| 5 counted | $21.9B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Johnson & Johnson announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $20.7B | $6.05B |
| Neuroscience | $3.8B | $14.6B |
| Immunology | $13.9B | $1.25B |
| Cardiometabolic | $2.6B | – |
| Other | $2.3B | – |
Johnson & Johnson has the most revenue at risk in oncology, but has spent the most on acquisitions in neuroscience. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Johnson & Johnson paid, not the sales it will bring in. Only one of the 5 companies it bought was already selling an approved product at closing (Intra-Cellular Therapies); the rest brought pipeline drugs whose sales are years away and may never arrive. The closest like-for-like figure is sales of the products Johnson & Johnson bought: $700M in 2025 (only from the closing date), against $43.4B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: J&J FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Johnson & Johnson’s announcement or filing in the table above.
See all 63 drugs on the patent cliff →Hetero's capsules are approved, but AbbVie still expects no US generic before 30 March 2032. FDA Orange Book
Amgen's Wezlana launched in January 2025, and several more biosimilars followed during the year. Stelara sales fell 41% in 2025. Center for Biosimilars